Publications (275) ATANASIO PANDIELLA ALONSO publications

2024

  1. Action Mechanism of Bioactive Compounds from Plants and Spices Mixture as Promising Anticancer Agents: In Silico Drug Design Predictions Targeting Cancer Cell Proliferation Through Cell Cycle Arrest Pathway

    Journal of Computational Biophysics and Chemistry

  2. ERK5 Interacts with Mitochondrial Glutaminase and Regulates Its Expression

    International Journal of Molecular Sciences, Vol. 25, Núm. 6

  3. Latent-Transforming Growth Factor β-Binding Protein 1/Transforming Growth Factor β1 Complex Drives Antitumoral Effects upon ERK5 Targeting in Melanoma

    American Journal of Pathology, Vol. 194, Núm. 8, pp. 1581-1591

  4. Multiple mechanisms contribute to acquired TRAIL resistance in multiple myeloma

    Cancer Cell International, Vol. 24, Núm. 1

  5. Ocoxin Oral Solution Triggers DNA Damage and Cell Death in Ovarian Cancer

    Nutrients, Vol. 16, Núm. 15

  6. Peptidylarginine deiminase 3 modulates response to neratinib in HER2 positive breast cancer

    Oncogenesis, Vol. 13, Núm. 1

  7. Strategies to boost antibody selectivity in oncology

    Trends in Pharmacological Sciences, Vol. 45, Núm. 12, pp. 1135-1149

  8. Synergistic effects of medicinal plants in combination with spices from algeria: Anticancer, antiangiogenic activities, and embrytoxicity studies

    Journal of Ethnopharmacology, Vol. 330

  9. T-reg transcriptomic signatures identify response to check-point inhibitors

    Scientific Reports, Vol. 14, Núm. 1

  10. Trastuzumab deruxtecan in breast cancer

    Critical Reviews in Oncology/Hematology, Vol. 198

  11. Understanding the Preclinical Efficacy of Antibody–Drug Conjugates

    International Journal of Molecular Sciences, Vol. 25, Núm. 23

2023

  1. An amino acid transporter subunit as an antibody-drug conjugate target in colorectal cancer

    Journal of experimental & clinical cancer research : CR, Vol. 42, Núm. 1, pp. 200

  2. An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs

    Cancer Letters, Vol. 554

  3. Chemical-proteomics Identify Peroxiredoxin-1 as an Actionable Target in Triple-negative Breast Cancer

    International Journal of Biological Sciences, Vol. 19, Núm. 6, pp. 1731-1747

  4. Considerations for the clinical development of immuno-oncology agents in cancer

    Frontiers in immunology, Vol. 14, pp. 1229575

  5. Etiopathogenic role of ERK5 signaling in sarcoma: prognostic and therapeutic implications

    Experimental and Molecular Medicine, Vol. 55, Núm. 6, pp. 1247-1257